Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PD-1/L1
Pharma
Keytruda's novel head and neck cancer nod comes with a limit
For the breakthrough perioperative head and neck cancer indication, Keytruda is only allowed in patients with PD-L1-positive tumors.
Angus Liu
Jun 13, 2025 10:50am
FDA limits Keytruda, Opdivo uses in stomach cancer
Jun 9, 2025 10:50am
Fierce Biotech
Are Lilly, Novartis eyeing the PD-1xVEGF field? Execs weigh in
Jun 4, 2025 1:00pm
ASCO: AZ looks to bring immunotherapy to early stomach cancer
Jun 1, 2025 8:00am
Incyte secures anal cancer nods years after FDA rejection
May 16, 2025 10:10am
Keytruda delivers trial win in some patients with ovarian cancer
May 15, 2025 10:56am
